ArticleFrontiers in public health2025
Breast cancer burden (1990-2040) in individuals aged 55 and above: a GBD 2021 analysis of global trends, sex-specific risk factors, and intervention impact.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 2-Hydroxy-1-naphthaldehyde-based organotin(IV) complexes: structural aspects, cytotoxicity, DNA binding interaction, and molecular docking.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
- Integrative immunogenomic and experimental characterization reveals CXCL9, CXCL13, CCL5 and CD74 as key oncogenic drivers in breast cancer.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer remains a leading cause of death among women, with incidence and mortality rates sharply increasing with age, particularly in individuals aged 55 and above. This study provides a comprehensive assessment of the global breast cancer burden in this high-risk demographic. Methods: Utilizing Global Burden of Disease (GBD) 2021 study data, we analyzed breast cancer incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for individuals aged 55 and older from 1990 to 2021. Temporal trends were quantified using age-standardized rates (ASRs) and Estimated Annual Percentage Changes (EAPCs). Population Attributable Fractions (PAFs) delineated sex-specific contributions of modifiable risk factors. A Bayesian age-period-cohort (BAPC) model projected the future burden to 2040, rigorously validated by sensitivity analysis. Crucially, an evidence-based scenario analysis was employed to model the potential impact of various public health interventions. Results: Globally, absolute breast cancer cases and deaths in the 55+ population significantly increased (1990-2021), despite a modest decline in the age-standardized mortality rate. Profound disparities emerged across Socio-Demographic Index (SDI) regions, with low-to-middle SDI regions experiencing sharp increases in incidence and mortality, contrasting with declining standardized mortality in high-SDI regions. Risk factor analysis revealed distinct sex-specific profiles: female DALY burden was predominantly driven by metabolic risks (e.g., high BMI), while male burden was overwhelmingly attributable to high alcohol consumption. Baseline projections to 2040 suggest rate stabilization; however, scenario analysis demonstrated high malleability: enhanced screening could avert millions of cases, whereas pessimistic scenarios (e.g., COVID-19 pandemic disruptions) could reverse current progress. Conclusion: The breast cancer burden in the aging population is substantial and increasingly concentrated in developing regions. The distinct risk profiles between sexes, combined with the profound potential of targeted interventions, underscore the urgent need for tailored, proactive, and resource-stratified public health strategies to mitigate the projected global burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.